Chris Boshoff: Pfizer in ASCO24

Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared a post on LinkedIn:

“We are excited to participate in ASCO24, where we will highlight our continued efforts to accelerate breakthrough medicines that help people with cancer live better and longer lives.

We are looking forward to key data presentations across our newly expanded portfolio, including new five-year results for our ALK inhibitor in advanced non-small cell lung cancer, which was selected for the official ASCO press program. We will also present additional evidence for several approved medicines and promising new data from our deep and diverse pipeline.”

Read further.
Source: Chris Boshoff/LinkedIn